| 1 |
De Lima M, Porter DL, Battiwalla M, et al. Proceedings from the National Cancer Institute′s Second International Workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: part Ⅲ. Prevention and treatment of relapse after allogeneic transplantation[J]. Biol Blood Marrow Transplant, 2014, 20(1): 4-13.
|
| 2 |
Rautenberg C, Germing U, Haas R, et al. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment[J]. Int J Mol Sci, 2019, 20(1): 228.
|
| 3 |
Schmid C, de Wreede LC, van Biezen A, et al. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation[J]. Haematologica, 2018, 103(2): 237-245.
|
| 4 |
Schmid C, Labopin M, Nagler A, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation[J]. Blood, 2012，119(6): 1599-1606.
|
| 5 |
Bhagat TD, Chen S, Bartenstein M, et al. Epigenetically aberrant stroma in MDS propagates disease via Wnt/β-Catenin activation[J]. Cancer Res, 2017, 77(18): 4846-4857.
|
| 6 |
Lee CJ, Savani BN, Mohty M, et al. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation[J]. Bone Marrow Transplant, 2019, 54(4): 519-530.
|
| 7 |
Orti G, Barba P, Fox L, et al. Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect[J]. Exp Hematol, 2017, 48：1-11.
|
| 8 |
Schroeder T, Rachlis E, Bug G, et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions-a retrospective multicenter analysis from the German Cooperative Transplant Study Group[J]. Biol Blood Marrow Transplant, 2015, 21(4)：653-660.
|
| 9 |
Schroeder T, Fröbel J, Cadeddu RP, et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation[J]. Leukemia, 2013, 27(9): 1910-1913.
|
| 10 |
Schroeder T, Rautenberg C, Haas R, et al. Hypomethylating agents after allogeneic blood stem cell transplantation[J]. Stem Cell Investig, 2016, 3：84.
|
| 11 |
DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML[J]. N Engl J Med, 2018, 378(25): 2386-2398.
|
| 12 |
Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia[J]. Blood, 2017, 130(6): 722-731.
|
| 13 |
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation[J]. N Engl J Med, 2017, 377(5): 454-464.
|
| 14 |
DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J]. Blood, 2019, 133(1)：7-17.
|
| 15 |
DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies[J]. Am J Hematol, 2018, 93(3)：401-407.
|
| 16 |
Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia[J]. Cancer Discov, 2014，4(3)：362-375.
|
| 17 |
Tsao T, Shi Y, Kornblau S, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells[J]. Ann Hematol, 2012，91(12)：1861-1870.
|
| 18 |
Bogenberger JM, Delman D, Hansen N, et al. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies[J]. Leuk Lymphoma, 2015，56(1)：226-229.
|
| 19 |
Ram R, Amit O, Zuckerman T, et al. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study[J]. Ann Hematol, 2019，98(8)：1927-1932.
|
| 20 |
Byrne M, Danielson N, Sengsayadeth S, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia [J]. Am J Hematol, 2020, 95(9)：1006-1014.
|